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patterns were assessed at 6 months following hospital discharge for patients who 
received only BMS and for patients with at least 1 DES. METHODS: A prospective, 
observational registry of 11 European countries grouped into 6 clusters recruited ACS 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
(97%) had 6-month data, of which 2842 (96%) received a stent at index PCI. The 
percentage of patients with at least 1 DES was 17% in the Czech Republic, 31% in 
Germany, 33% in Austria-Hungary, 33% in Belgium-The Netherlands, 37% in the 
Nordic countries, and 81% in Greece. The percentage of patients taking dual anti-
platelet therapy at hospital discharge ranged from 93% in Belgium-The Netherlands 
to 100% in Greece for BMS only and from 93% in Belgium-The Netherlands to 100% 
in Czech Republic for patients with DES. At 6 months, the percentage of patients 
taking dual antiplatelet therapy ranged from 45% in Czech Republic to 97% in Greece 
for BMS-only patients and from 83% in Belgium-The Netherlands to 97% in Greece 
for patients with DES. Aspirin use ranged from 89% to 100% across the countries 
and type of stent. CONCLUSIONS: Use of DES versus BMS varied among the Euro-
pean countries. In patients with BMS, there was marked variability with clopidogrel 
use at 6 months; whereas, in patients with DES, clopidogrel was used more frequently 
and with less variability.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for all patients with acute coronary syndrome 
(ACS). The variations in antiplatelet treatment patterns at 6 months following hospital 
discharge were assessed in patients with unstable angina (UA), non-ST-elevation 
myocardial infarction (NSTEMI), and ST-elevation MI (STEMI) undergoing percuta-
neous intervention (PCI). METHODS: A prospective, observational registry of 11 
European countries grouped into 6 clusters recruited acute coronary syndrome (ACS) 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
patients (97%) had 6 month data; 51% of patients presented with STEMI and 49% 
with UA/NSTEMI. The median age was 62 yrs. At 6 months following hospital dis-
charge, the percentage of UA/NSTEMI and STEMI patients using clopidogrel, respec-
tively, was 70% and 40% in the Czech Republic, 84% and 89% in Germany, 98% 
and 99% in Greece, 78% and 81% in the Nordic countries, 93% and 94% in Austria 
and Hungary, and 81% and 88% in Belgium and the The Netherlands. The percentage 
of UA/NSTEMI and STEMI patients taking aspirin, respectively, was 98% and 99% 
in the Czech Republic, 89% and 90% in Germany, 97% and 100% in Greece, 95% 
and 93% in the Nordic countries, 94% and 96% in Austria and Hungary, and 91% 
and 94% in Belgium and the The Netherlands. CONCLUSIONS: Use of clopidogrel 
varied considerably between European countries at 6 months after discharge, whereas 
the majority (≥90%) of patients continued to use aspirin. Results suggest that both 
physician and patient education on continuing dual antiplatelet therapy may be 
needed.
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Germany, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international prospec-
tive, observational study recruited ACS patients undergoing percutaneous coronary 
intervention (PCI), April 2008–March 2009, capturing practice patterns, resource use 
and QoL. RESULTS: 500 ACS-PCI patients (out of the 508 recruited) were eligible: 
median age 63 yrs (IQR 53–72), median weight 82 kg (IQR 74–92), 23% female, 
24% Type II diabetics, and 27% prior myocardial infarction (MI). Index diagnosis 
was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation 
MI (STEMI)-47%. Almost all patients (96%) received stents: 68% bare metal stents 
(BMS) only, 29% drug eluting stents (DES) only and 3% both. Time from start of 
ACS symptoms to PCI was 3 days or less in 91% of UA/NSTEMI patients and 1 day 
or less in 97% of STEMI patients. Oral antiplatelet medications with loading dose 
(LD) used: aspirin-86% and clopidogrel-93%. Clopidogrel LD was administered in 
the ambulance-7%, previous hospital-8%, emergency room-32%, CCU or ICU-23%, 
catheterization lab-25%, other ward 5%. LD was administered just before or direct 
after PCI in 79% of cases. The clopidogrel LD was 600 mg in 68% and 300 mg in 
24% of cases and in-hospital maintenance dose (MD) was 75 mg in 98%. At time of 
hospital discharge, 92% of discharged patients were receiving clopidogrel (discharge 
dose 75 mg in all cases). QoL in discharged patients was good: median EQ-5D health 
state index at 0.85 (IQR 0.73–1.00). CONCLUSIONS: These real life data reﬂ ect 
treatment patterns among ACS patients managed by PCI in Germany in 2008–2009. 
Timing and place of antiplatelet loading differ between patients. The QoL of patients 
at discharge was high.
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OBJECTIVES: This study estimated market shares for six statins based on 1) the 
literature-determined lipid-lowering potential of the drugs, and 2) the distribution of 
U.S. adults depending on the amount of lipid-lowering they required. Estimated 
market shares were compared with actual market shares. METHODS: Two panels 
(1999–2000 and 2001–2002) from the National Health and Nutrition Examination 
Survey (NHANES) provided interview, demographic, and laboratory data for 3324 
people >20 years of age who were not taking a statin. In accordance with the ATP III 
Guidelines, coronary heart disease (CHD) and CHD-risk-equivalent events including 
diabetes, other risk factors such as smoking and high blood pressure, and Framingham 
scores to obtain 10-year risk estimates were identiﬁ ed and calculated, respectively for 
each person, along with percentage LDL-C lowering required to reach his or her 
LDL-C goal. Depending on the amount of lowering needed and on whether the 
individual had a liver condition, hence, enhanced risk of rhabdomyolysis, a particular 
statin or particular statins with equal probabilities were assigned to the individual; 
e.g., a person without a liver condition requiring 50% lowering of LDL-C would be 
assigned rosuvastatin or atorvastatin, each with probability = 0.5. RESULTS: Of 1643 
men surveyed, 57.88% were in the lowest-risk group (0–1 risk factors); 14.36% were 
in the highest-risk group (CHD or CHD-risk-equivalent). For the 1681 women, these 
percentages were 73.11% and 11.30%, respectively. Of people needing a statin, 
73.74% needed LDL-C lowering by <25%; only 1.16% required LDL-C lowering of 
>60%. Therapeutic market shares were estimated at 20.11% (rosuvastatin); 18.94% 
(atorvastatin); 17.89% (simvastatin); 16.96% (lovastatin); 13.05% (ﬂ uvastatin); and 
13.05% (pravastatin). CONCLUSIONS: Actual market shares are signiﬁ cantly differ-
ent from market shares based on lipid-lowering considerations. Explanations include 
direct-to-consumer advertising; varying pricing strategies; and clinical trials for addi-
tional indications and subpopulations conducted only by the market leaders.
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OBJECTIVES: By creating incentives around quality and efﬁ ciency, there exists con-
sideration to bundle hospital and physician payments around the episodes of inpatient 
surgery. We provided current payments around surgical episodes including the degree 
to which different types of providers are involved. In particular, we looked at the most 
expensive procedure performed commonly on the elderly: coronary artery bypass graft 
(CABG) surgery. METHODS: The study was based on complete national U.S. claims 
data. Managed care patients were excluded (16% in 2005) from the study because 
service provided to them was not consistently captured in the data set. We also 
excluded patients who were less than 65 years of age or over 99, and those not enrolled 
in the data set at the time of their procedures (4%). Also excluded were patients who 
were nursing home residents before surgery. Patients undergoing CABG were identi-
ﬁ ed using ICD-9 codes. Price-standardized payments from the date of admission for 
the index procedure to 30 days post-discharge were determined and categorized by 
payment type (hospital, physician, and post-acute care) and sub-type. RESULTS: The 
average total payment around an inpatient surgery episode was $45,358 for CABG. 
Hospital payments accounted for the largest of total payments (60% of the procedure), 
followed by physician payments (13%). Diagnosis-Related Group (DRG) payments 
and surgeon and anesthesia professional payments together accounted for 65% of 
total payments. Among payment types potentially leveraged by bundled payments, 
30-day readmissions accounted for 10% of total payments around surgical episodes. 
Post-acute care, including home health care and extended care facilities, accounted for 
7% of total payments. CONCLUSIONS: Payments for potentially mutable services, 
including outlier payments, 30-day readmissions, and post-acute care are considerable 
and might be reduced by incentives for hospitals and physicians to improve quality 
and efﬁ ciency.
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OBJECTIVES: Construct the disease management model for patients with Atrial 
Fibrillation (AF) in Greece, according to initial therapeutic approach. METHODS: 
The analysis was based on data from patient records of 149 geographically distributed 
cardiologists, extracted via strictly structured questionnaire-based interviews. Partici-
